

Sarah E Pinder

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9580432/publications.pdf>

Version: 2024-02-01

338
papers

26,432
citations

7568

77
h-index

7950

149
g-index

349
all docs

349
docs citations

349
times ranked

28403
citing authors

#	ARTICLE	IF	CITATIONS
1	The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. <i>Nature</i> , 2012, 486, 346-352.	27.8	4,708
2	The somatic mutation profiles of 2,433 breast cancers refine their genomic and transcriptomic landscapes. <i>Nature Communications</i> , 2016, 7, 11479.	12.8	1,221
3	Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. <i>Nature Medicine</i> , 2018, 24, 628-637.	30.7	649
4	Expression of luminal and basal cytokeratins in human breast carcinoma. <i>Journal of Pathology</i> , 2004, 203, 661-671.	4.5	516
5	Terahertz pulsed spectroscopy of freshly excised human breast cancer. <i>Optics Express</i> , 2009, 17, 12444.	3.4	516
6	High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. <i>International Journal of Cancer</i> , 2005, 116, 340-350.	5.1	500
7	Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial. <i>Lancet Oncology</i> , The, 2011, 12, 21-29.	10.7	476
8	An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer. <i>Genome Biology</i> , 2007, 8, R157.	9.6	433
9	Proliferation markers and survival in early breast cancer: A systematic review and meta-analysis of 85 studies in 32,825 patients. <i>Breast</i> , 2008, 17, 323-334.	2.2	353
10	Pathological prognostic factors in breast cancer. <i>Critical Reviews in Oncology/Hematology</i> , 1999, 31, 209-223.	4.4	278
11	High-resolution aCGH and expression profiling identifies a novel genomic subtype of ER negative breast cancer. <i>Genome Biology</i> , 2007, 8, R215.	9.6	275
12	Addressing overtreatment of screen detected DCIS; the LORIS trial. <i>European Journal of Cancer</i> , 2015, 51, 2296-2303.	2.8	266
13	Columnar Cell Lesions of the Breast: The Missing Link in Breast Cancer Progression?. <i>American Journal of Surgical Pathology</i> , 2005, 29, 734-746.	3.7	256
14	Pathological prognostic factors in breast cancer. III. Vascular invasion: relationship with recurrence and survival in a large study with long-term follow-up. <i>Histopathology</i> , 1994, 24, 41-47.	2.9	254
15	Phyllodes tumours of the breast: a clinicopathological review of thirty-two cases. <i>Histopathology</i> , 1995, 27, 205-218.	2.9	237
16	Estrogen receptor-negative breast carcinomas: a review of morphology and immunophenotypical analysis. <i>Modern Pathology</i> , 2005, 18, 26-35.	5.5	232
17	Somatic mutations reveal asymmetric cellular dynamics in the early human embryo. <i>Nature</i> , 2017, 543, 714-718.	27.8	229
18	Diagnosis of axillary nodal metastases by ultrasound-guided core biopsy in primary operable breast cancer. <i>British Journal of Cancer</i> , 2003, 89, 1310-1313.	6.4	225

#	ARTICLE	IF	CITATIONS
19	A gene-expression signature to predict survival in breast cancer across independent data sets. <i>Oncogene</i> , 2007, 26, 1507-1516.	5.9	225
20	Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres. <i>Journal of Pathology</i> , 2003, 199, 418-423.	4.5	223
21	Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma. <i>British Journal of Cancer</i> , 2004, 91, 1532-1542.	6.4	217
22	A model for predicting non-sentinel lymph node metastatic disease when the sentinel lymph node is positive. <i>British Journal of Surgery</i> , 2008, 95, 302-309.	0.3	211
23	Updated UK Recommendations for HER2 assessment in breast cancer. <i>Journal of Clinical Pathology</i> , 2015, 68, 93-99.	2.0	203
24	Radiotherapy or tamoxifen after conserving surgery for breast cancers of excellent prognosis: British Association of Surgical Oncology (BASO) II trial. <i>European Journal of Cancer</i> , 2013, 49, 2294-2302.	2.8	189
25	Bcl-2 Is a Prognostic Marker in Breast Cancer Independently of the Nottingham Prognostic Index. <i>Clinical Cancer Research</i> , 2006, 12, 2468-2475.	7.0	188
26	Alpha α 6 integrin is necessary for the tumorigenicity of a stem cell-like subpopulation within the MCF7 breast cancer cell line. <i>International Journal of Cancer</i> , 2008, 122, 298-304.	5.1	187
27	Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer. <i>Endocrine-Related Cancer</i> , 2005, 12, S99-S111.	3.1	185
28	Survival of invasive breast cancer according to the Nottingham Prognostic Index in cases diagnosed in 1990-1999. <i>European Journal of Cancer</i> , 2007, 43, 1548-1555.	2.8	182
29	Sentinel Node Biopsy Using a Magnetic Tracer Versus Standard Technique: The SentiMAG Multicentre Trial. <i>Annals of Surgical Oncology</i> , 2014, 21, 1237-1245.	1.5	182
30	Screening interval breast cancers: mammographic features and prognosis factors. <i>Radiology</i> , 1996, 199, 811-817.	7.3	180
31	Prognostic factors for patients with hepatic metastases from breast cancer. <i>British Journal of Cancer</i> , 2003, 89, 284-290.	6.4	177
32	Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration. <i>Annals of Oncology</i> , 2015, 26, 1280-1291.	1.2	177
33	Selectin Ligand Sialyl-Lewis x Antigen Drives Metastasis of Hormone-Dependent Breast Cancers. <i>Cancer Research</i> , 2011, 71, 7683-7693.	0.9	171
34	Comparing Breast Cancer Multiparameter Tests in the OPTIMA Prelim Trial: No Test Is More Equal Than the Others. <i>Journal of the National Cancer Institute</i> , 2016, 108, djw050.	6.3	166
35	An immunohistochemical study of metaplastic spindle cell carcinoma, phyllodes tumor and fibromatosis of the breast. <i>Human Pathology</i> , 2003, 34, 1009-1015.	2.0	163
36	Assessment of the new proliferation marker MIB1 in breast carcinoma using image analysis: associations with other prognostic factors and survival. <i>British Journal of Cancer</i> , 1995, 71, 146-149.	6.4	160

#	ARTICLE	IF	CITATIONS
37	Pathological prognostic factors in breast cancer. IV: Should you be a typer or a grader? A comparative study of two histological prognostic features in operable breast carcinoma. <i>Histopathology</i> , 1995, 27, 219-226.	2.9	158
38	Best Practice No 176: Updated recommendations for HER2 testing in the UK. <i>Journal of Clinical Pathology</i> , 2004, 57, 233-237.	2.0	156
39	E-cadherin expression in invasive non-lobular carcinoma of the breast and its prognostic significance. <i>Histopathology</i> , 2005, 46, 685-693.	2.9	150
40	Brain metastases from breast cancer: identification of a high-risk group. <i>Clinical Oncology</i> , 2004, 16, 345-349.	1.4	143
41	The role of PTEN and its signalling pathways, including AKT, in breast cancer; an assessment of relationships with other prognostic factors and with outcome. <i>Journal of Pathology</i> , 2004, 204, 93-100.	4.5	138
42	Neuroendocrine differentiation and prognosis in breast adenocarcinoma. <i>Histopathology</i> , 2002, 40, 215-222.	2.9	136
43	Minichromosome Maintenance Protein 2 Is a Strong Independent Prognostic Marker in Breast Cancer. <i>Journal of Clinical Oncology</i> , 2003, 21, 4306-4313.	1.6	136
44	Total loss of MHC class I is an independent indicator of good prognosis in breast cancer. <i>International Journal of Cancer</i> , 2005, 117, 248-255.	5.1	134
45	Randomized clinical trial comparing radioisotope occult lesion localization and wire-guided excision for biopsy of occult breast lesions. <i>British Journal of Surgery</i> , 2004, 91, 1575-1577.	0.3	128
46	Correlation of Histologic Prognostic Factors in Core Biopsies and Therapeutic Excisions of Invasive Breast Carcinoma. <i>American Journal of Surgical Pathology</i> , 2003, 27, 11-15.	3.7	127
47	Prognostic value of lymphovascular invasion in women with lymph node negative invasive breast carcinoma. <i>European Journal of Cancer</i> , 2006, 42, 357-362.	2.8	127
48	Laboratory handling and histology reporting of breast specimens from patients who have received neoadjuvant chemotherapy. <i>Histopathology</i> , 2007, 50, 409-417.	2.9	127
49	Over-expression of ST3Gal-I promotes mammary tumorigenesis. <i>Glycobiology</i> , 2010, 20, 1241-1250.	2.5	124
50	Histologic Grading of Breast Cancer: Linkage of Patient Outcome with Level of Pathologist Agreement. <i>Modern Pathology</i> , 2000, 13, 730-735.	5.5	120
51	HER2 testing in the UK: further update to recommendations. <i>Journal of Clinical Pathology</i> , 2008, 61, 818-824.	2.0	119
52	C-erbB-3 in human breast carcinoma: expression and relation to prognosis and established prognostic indicators. <i>British Journal of Cancer</i> , 1996, 74, 229-233.	6.4	118
53	Bone metastases from breast carcinoma: histopathological " radiological correlations and prognostic features. <i>British Journal of Cancer</i> , 2003, 89, 660-665.	6.4	117
54	Ductal carcinoma in situ of the breast: correlation between mammographic and pathologic findings.. <i>American Journal of Roentgenology</i> , 1994, 162, 1307-1311.	2.2	116

#	ARTICLE	IF	CITATIONS
55	A new pathological system for grading DCIS with improved prediction of local recurrence: results from the UKCCCR/ANZ DCIS trial. <i>British Journal of Cancer</i> , 2010, 103, 94-100.	6.4	115
56	The diagnosis and management of pre-invasive breast disease: Ductal carcinoma in situ (DCIS) and atypical ductal hyperplasia (ADH) – current definitions and classification. <i>Breast Cancer Research</i> , 2003, 5, 254-7.	5.0	112
57	NHS Breast Screening multidisciplinary working group guidelines for the diagnosis and management of breast lesions of uncertain malignant potential on core biopsy (B3 lesions). <i>Clinical Radiology</i> , 2018, 73, 682-692.	1.1	107
58	X-ray refraction effects: application to the imaging of biological tissues. <i>British Journal of Radiology</i> , 2003, 76, 301-308.	2.2	103
59	Excision biopsy findings of patients with breast needle core biopsies reported as suspicious of malignancy (B4) or lesion of uncertain malignant potential (B3). <i>Histopathology</i> , 2003, 42, 331-336.	2.9	100
60	Regulation of p53 tetramerization and nuclear export by ARC. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 20826-20831.	7.1	100
61	Using array-comparative genomic hybridization to define molecular portraits of primary breast cancers. <i>Oncogene</i> , 2007, 26, 1959-1970.	5.9	97
62	Genomic Complexity Profiling Reveals That HORMAD1 Overexpression Contributes to Homologous Recombination Deficiency in Triple-Negative Breast Cancers. <i>Cancer Discovery</i> , 2015, 5, 488-505.	9.4	97
63	Best Practice No 179: Guidelines for breast needle core biopsy handling and reporting in breast screening assessment. <i>Journal of Clinical Pathology</i> , 2004, 57, 897-902.	2.0	95
64	Residual proliferative cancer burden to predict long-term outcome following neoadjuvant chemotherapy. <i>Annals of Oncology</i> , 2015, 26, 75-80.	1.2	95
65	Interobserver reproducibility in the diagnosis of flat epithelial atypia of the breast. <i>Modern Pathology</i> , 2006, 19, 172-179.	5.5	94
66	ROR1 ³ + Innate Lymphoid Cells Promote Lymph Node Metastasis of Breast Cancers. <i>Cancer Research</i> , 2017, 77, 1083-1096.	0.9	93
67	c-erbB-4 protein expression in human breast cancer. <i>British Journal of Cancer</i> , 2000, 82, 1163-1170.	6.4	92
68	Intraoperative Assessment of Tumor Resection Margins in Breast-Conserving Surgery Using ¹⁸ F-FDG Cerenkov Luminescence Imaging: A First-in-Human Feasibility Study. <i>Journal of Nuclear Medicine</i> , 2017, 58, 891-898.	5.0	91
69	Ductal carcinoma in situ (DCIS): pathological features, differential diagnosis, prognostic factors and specimen evaluation. <i>Modern Pathology</i> , 2010, 23, S8-S13.	5.5	90
70	Metaplastic carcinoma of the breast arising within complex sclerosing lesion: a report of five cases. <i>Histopathology</i> , 2000, 36, 203-209.	2.9	88
71	An immunohistochemical examination of the expression of E-cadherin, β - and γ -catenins, and β - and γ -integrins in invasive breast cancer. , 1999, 187, 523-529.		87
72	Gamma linolenic acid with tamoxifen as primary therapy in breast cancer. , 2000, 85, 643-648.		85

#	ARTICLE	IF	CITATIONS
73	Geminin predicts adverse clinical outcome in breast cancer by reflecting cell-cycle progression. <i>Journal of Pathology</i> , 2004, 204, 121-130.	4.5	85
74	Neoadjuvant Therapy in Early Breast Cancer: Treatment Considerations and Common Debates in Practice. <i>Clinical Oncology</i> , 2017, 29, 642-652.	1.4	85
75	Breast cancer diagnosis using scattered X-rays. <i>Journal of Synchrotron Radiation</i> , 2000, 7, 348-352.	2.4	84
76	Classification of terahertz-pulsed imaging data from excised breast tissue. <i>Journal of Biomedical Optics</i> , 2012, 17, 016005.	2.6	84
77	Phase II Randomized Preoperative Window-of-Opportunity Study of the PI3K Inhibitor Pictilisib Plus Anastrozole Compared With Anastrozole Alone in Patients With Estrogen Receptor-Positive Breast Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 1987-1994.	1.6	84
78	The importance of the histologic grade of invasive breast carcinoma and response to chemotherapy. <i>Cancer</i> , 1998, 83, 1529-1539.	4.1	83
79	A consensus prognostic gene expression classifier for ER positive breast cancer. <i>Genome Biology</i> , 2006, 7, R101.	9.6	82
80	Prediction of local recurrence of ductal carcinoma in situ of the breast using five histological classifications: A comparative study with long follow-up. <i>Human Pathology</i> , 1998, 29, 915-923.	2.0	81
81	Prognostic and predictive factors in primary breast cancer and their role in patient management: The Nottingham Breast Team. <i>European Journal of Surgical Oncology</i> , 2001, 27, 229-238.	1.0	79
82	Comparison of basal-like triple-negative breast cancer defined by morphology, immunohistochemistry and transcriptional profiles. <i>Modern Pathology</i> , 2013, 26, 955-966.	5.5	79
83	The pathological and radiological features of screen-detected breast cancers diagnosed following arbitration of discordant double reading opinions. <i>Clinical Radiology</i> , 2005, 60, 1182-1187.	1.1	78
84	Integrated genomic analysis of triple-negative breast cancers reveals novel microRNAs associated with clinical and molecular phenotypes and sheds light on the pathways they control. <i>BMC Genomics</i> , 2013, 14, 643.	2.8	76
85	The positive predictive value of mammographic signs: A review of 425 non-palpable breast lesions. <i>Clinical Radiology</i> , 1996, 51, 277-281.	1.1	72
86	Impact of a national external quality assessment scheme for breast pathology in the UK. <i>Journal of Clinical Pathology</i> , 2006, 59, 138-145.	2.0	72
87	Predicting Invasion in Mammographically Detected Microcalcification. <i>Clinical Radiology</i> , 2001, 56, 828-832.	1.1	71
88	Loss of CD59 expression in breast tumours correlates with poor survival. <i>Journal of Pathology</i> , 2003, 200, 633-639.	4.5	70
89	Age at diagnosis and distant metastasis in breast cancer – A surprising inverse relationship. <i>European Journal of Cancer</i> , 2014, 50, 1697-1705.	2.8	70
90	Germline CDH1 mutations in bilateral lobular carcinoma in situ. <i>British Journal of Cancer</i> , 2014, 110, 1053-1057.	6.4	70

#	ARTICLE	IF	CITATIONS
91	Systematic review of high-intensity focused ultrasound ablation in the treatment of breast cancer. <i>British Journal of Surgery</i> , 2015, 102, 873-882.	0.3	70
92	False-negative Breast Screening Assessment. What Lessons Can We Learn?. <i>Clinical Radiology</i> , 2001, 56, 385-388.	1.1	68
93	Prognostic significance of serum c-erbB-2 protein in breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 1996, 40, 251-255.	2.5	67
94	E-cadherin as a prognostic indicator in primary breast cancer. <i>British Journal of Cancer</i> , 2001, 85, 1958-1963.	6.4	67
95	Preoperative assessment of prognostic factors in breast cancer. <i>Journal of Clinical Pathology</i> , 2001, 54, 20-24.	2.0	66
96	Is Mammographic Spiculation an Independent, Good Prognostic Factor in Screening-Detected Invasive Breast Cancer?. <i>American Journal of Roentgenology</i> , 2006, 187, 1377-1380.	2.2	66
97	Screen detected ductal carcinoma in situ (DCIS): overdiagnosis or an obligate precursor of invasive disease?. <i>Journal of Medical Screening</i> , 2001, 8, 149-151.	2.3	65
98	Anti-Folate Receptor Alpha-Targeted Antibody Therapies Restrict the Growth of Triple-negative Breast Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 5098-5111.	7.0	65
99	Deposition of superparamagnetic iron-oxide nanoparticles in axillary sentinel lymph nodes following subcutaneous injection. <i>Histopathology</i> , 2013, 62, 481-486.	2.9	63
100	Use of a handheld terahertz pulsed imaging device to differentiate benign and malignant breast tissue. <i>Biomedical Optics Express</i> , 2017, 8, 2932.	2.9	63
101	The impact of core-biopsy on pre-operative diagnosis rate of screen detected breast cancers. <i>Clinical Radiology</i> , 1996, 51, 562-565.	1.1	62
102	Local recurrence after simple mastectomy. <i>British Journal of Surgery</i> , 2005, 81, 386-389.	0.3	62
103	HER2 testing in the UK: recommendations for breast and gastric in-situ hybridisation methods. <i>Journal of Clinical Pathology</i> , 2011, 64, 649-653.	2.0	62
104	Risk factors for the development of invasive cancer in unresected ductal carcinoma in situ. <i>European Journal of Surgical Oncology</i> , 2018, 44, 429-435.	1.0	62
105	The accuracy of breast ultrasound in the evaluation of clinically benign discrete, symptomatic breast lumps. <i>Clinical Radiology</i> , 1998, 53, 490-492.	1.1	61
106	PAK4 promotes kinase-independent stabilization of RhoU to modulate cell adhesion. <i>Journal of Cell Biology</i> , 2015, 211, 863-879.	5.2	61
107	MYC amplification in breast cancer: a chromogenic in situ hybridisation study. <i>Journal of Clinical Pathology</i> , 2006, 60, 1017-1023.	2.0	58
108	Automated Classification of Breast Cancer Stroma Maturity From Histological Images. <i>IEEE Transactions on Biomedical Engineering</i> , 2017, 64, 2344-2352.	4.2	57

#	ARTICLE	IF	CITATIONS
109	Spindle cell carcinoma of the breast: a case series of a rare histological subtype. <i>European Journal of Surgical Oncology</i> , 2003, 29, 600-603.	1.0	56
110	Reading the prognosis of the individual with breast cancer. <i>European Journal of Cancer</i> , 2007, 43, 1545-1547.	2.8	56
111	Breast imaging findings in women with BRCA1- and BRCA2-associated breast carcinoma. <i>Clinical Radiology</i> , 2004, 59, 895-902.	1.1	55
112	Prognostic significance of BRCA1 expression in sporadic breast carcinomas. <i>Journal of Pathology</i> , 2003, 200, 207-213.	4.5	54
113	Radiological and pathological size estimations of pure ductal carcinoma in situ of the breast, specimen handling and the influence on the success of breast conservation surgery: a review of 2564 cases from the Sloane Project. <i>British Journal of Cancer</i> , 2010, 102, 285-293.	6.4	54
114	Is ipsilateral mammography worthwhile in paget's disease of the breast?. <i>Clinical Radiology</i> , 1996, 51, 35-38.	1.1	53
115	OPTIMA prelim: a randomised feasibility study of personalised care in the treatment of women with early breast cancer. <i>Health Technology Assessment</i> , 2016, 20, 1-202.	2.8	53
116	Management and 5-year outcomes in 9938 women with screen-detected ductal carcinoma in situ: the UK Sloane Project. <i>European Journal of Cancer</i> , 2018, 101, 210-219.	2.8	52
117	Mammographic features of ductal carcinoma in situ (DCIS) present on previous mammography. <i>Clinical Radiology</i> , 1999, 54, 644-646.	1.1	51
118	Sentinel node biopsy for breast cancer may have little to offer four-node-samplers. <i>European Journal of Cancer</i> , 2001, 37, 1076-1080.	2.8	49
119	Non-operative breast pathology: columnar cell lesions. <i>Journal of Clinical Pathology</i> , 2006, 60, 1307-1312.	2.0	49
120	The QuinteT Recruitment Intervention supported five randomized trials to recruit to target: a mixed-methods evaluation. <i>Journal of Clinical Epidemiology</i> , 2019, 106, 108-120.	5.0	49
121	A randomised trial of primary tamoxifen versus mastectomy plus adjuvant tamoxifen in fit elderly women with invasive breast carcinoma of high oestrogen receptor content: long-term results at 20 years of follow-up. <i>Annals of Oncology</i> , 2012, 23, 2296-2300.	1.2	48
122	Screening-detected and symptomatic ductal carcinoma in situ: mammographic features with pathologic correlation.. <i>Radiology</i> , 1994, 191, 237-240.	7.3	47
123	Pure mucinous breast cancer-mammographic and ultrasound findings. <i>Clinical Radiology</i> , 1996, 51, 421-424.	1.1	47
124	When have Mammographic Calcifications been Adequately Sampled at Needle Core Biopsy?. <i>Clinical Radiology</i> , 2000, 55, 548-553.	1.1	47
125	Ultrasound Guided Core Biopsy of Suspicious Mammographic Calcifications Using High Frequency and Power Doppler Ultrasound. <i>Clinical Radiology</i> , 2000, 55, 390-394.	1.1	47
126	Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL): an overview of presentation and pathogenesis and guidelines for pathological diagnosis and management. <i>Histopathology</i> , 2019, 75, 787-796.	2.9	45

#	ARTICLE	IF	CITATIONS
127	The expression of alpha B-crystallin in epithelial tumours: A useful tumour marker?. <i>Journal of Pathology</i> , 1994, 174, 209-215.	4.5	44
128	Breast pathology practice: most common problems in a consultation service. <i>Histopathology</i> , 2005, 47, 445-457.	2.9	44
129	Neoadjuvant Chemotherapy: Not the Best Option in Estrogen Receptor-Positive, HER2-Negative, Invasive Classical Lobular Carcinoma of the Breast?. <i>Journal of Clinical Oncology</i> , 2010, 28, 3552-3554.	1.6	44
130	Expression of p27kip1 in breast cancer and its prognostic significance. <i>Journal of Pathology</i> , 2003, 201, 451-459.	4.5	43
131	Is the Presence of Mammographic Comedo Calcification Really a Prognostic Factor for Small Screen-detected Invasive Breast Cancers?. <i>Clinical Radiology</i> , 2003, 58, 54-62.	1.1	43
132	The manufacture and assessment of tissue microarrays: suggestions and criteria for analysis, with breast cancer as an example. <i>Journal of Clinical Pathology</i> , 2013, 66, 169-177.	2.0	43
133	Aldehyde dehydrogenase and estrogen receptor define a hierarchy of cellular differentiation in the normal human mammary epithelium. <i>Breast Cancer Research</i> , 2014, 16, R52.	5.0	43
134	Genetic predisposition to ductal carcinoma in situ of the breast. <i>Breast Cancer Research</i> , 2016, 18, 22.	5.0	43
135	Breast cancer biomarkers in clinical testing: analysis of a UK national external quality assessment scheme for immunocytochemistry and in situ hybridisation database containing results from 199 300 patients. <i>Journal of Pathology: Clinical Research</i> , 2018, 4, 262-273.	3.0	43
136	Predictors of pathological complete response to neoadjuvant treatment and changes to post-neoadjuvant HER2 status in HER2-positive invasive breast cancer. <i>Modern Pathology</i> , 2021, 34, 1271-1281.	5.5	43
137	Size of invasive breast cancer and risk of local recurrence after breast-conservation therapy. <i>European Journal of Cancer</i> , 2003, 39, 2462-2469.	2.8	42
138	Growth Hormone Is Secreted by Normal Breast Epithelium upon Progesterone Stimulation and Increases Proliferation of Stem/Progenitor Cells. <i>Stem Cell Reports</i> , 2014, 2, 780-793.	4.8	42
139	An audit of "equivocal" (C3) and "suspicious" (C4) categories in fine needle aspiration cytology of the breast. <i>Cytopathology</i> , 2001, 12, 219-226.	0.7	41
140	Loss of CD55 Is Associated with Aggressive Breast Tumors. <i>Clinical Cancer Research</i> , 2004, 10, 2797-2803.	7.0	41
141	The value of immunohistochemistry in sentinel lymph node histopathology in breast cancer. <i>British Journal of Cancer</i> , 2005, 92, 2201-2205.	6.4	41
142	Tumor-Infiltrating B Lymphocyte Profiling Identifies IgG-Biased, Clonally Expanded Prognostic Phenotypes in Triple-Negative Breast Cancer. <i>Cancer Research</i> , 2021, 81, 4290-4304.	0.9	40
143	Upregulation of MICA on high-grade invasive operable breast carcinoma. <i>Cancer Immunity</i> , 2007, 7, 17.	3.2	40
144	Genetic Predisposition to In Situ and Invasive Lobular Carcinoma of the Breast. <i>PLoS Genetics</i> , 2014, 10, e1004285.	3.5	39

#	ARTICLE	IF	CITATIONS
145	Mycobacterial cervical lymphadenitis in children: can histological assessment help differentiate infections caused by non-tuberculous mycobacteria from Mycobacterium tuberculosis?. <i>Histopathology</i> , 1993, 22, 59-64.	2.9	38
146	Radiological features of papillary carcinoma of the breast. <i>Clinical Radiology</i> , 1997, 52, 865-868.	1.1	38
147	Routine audit of breast fine needle aspiration (FNA) cytology specimens and aspirator inadequate rates. <i>Cytopathology</i> , 1997, 8, 236-247.	0.7	38
148	A tumor DNA complex aberration index is an independent predictor of survival in breast and ovarian cancer. <i>Molecular Oncology</i> , 2015, 9, 115-127.	4.6	38
149	Correlations between the mammographic features of ductal carcinoma In situ (DCIS) and C-erbB-2 oncogene expression. <i>Clinical Radiology</i> , 1994, 49, 559-562.	1.1	37
150	Growth pattern of ductal carcinoma in situ (DCIS): a retrospective analysis based on mammographic findings. <i>British Journal of Cancer</i> , 2001, 85, 225-227.	6.4	37
151	Expression of E2F-4 in invasive breast carcinomas is associated with poor prognosis. <i>Journal of Pathology</i> , 2004, 203, 754-761.	4.5	37
152	Challenges in the management of pleomorphic lobular carcinoma in situ of the breast. <i>Breast</i> , 2013, 22, 194-196.	2.2	37
153	P-glycoprotein expression is associated with sestamibi washout in primary hyperparathyroidism. <i>British Journal of Surgery</i> , 2007, 94, 1491-1495.	0.3	36
154	Review of the national external quality assessment (EQA) scheme for breast pathology in the UK. <i>Journal of Clinical Pathology</i> , 2017, 70, 51-57.	2.0	36
155	Cancer-associated hypersialylated MUC1 drives the differentiation of human monocytes into macrophages with a pathogenic phenotype. <i>Communications Biology</i> , 2020, 3, 644.	4.4	36
156	The role of pre-operative diagnosis in breast cancer. <i>Histopathology</i> , 1996, 28, 563-566.	2.9	35
157	The detection of ductal carcinoma in situ at mammographic screening enables the diagnosis of small, grade 3 invasive tumours. <i>British Journal of Cancer</i> , 1997, 75, 542-544.	6.4	35
158	Loss of Heterozygosity in Bilateral Breast Cancer. <i>Breast Cancer Research and Treatment</i> , 2000, 64, 241-251.	2.5	35
159	Patterns of metastatic breast carcinoma: influence of tumour histological grade. <i>Clinical Radiology</i> , 2004, 59, 1094-1098.	1.1	35
160	Clinical Value of Epidermal Growth Factor Receptor Expression in Primary Breast Cancer. <i>Advances in Anatomic Pathology</i> , 2005, 12, 271-273.	4.3	35
161	Lymphatic drainage pathways of the breast and the upper limb. <i>Nuclear Medicine Communications</i> , 2009, 30, 427-430.	1.1	35
162	Two E-selectin ligands, BST-2 and LGALS3BP, predict metastasis and poor survival of ER-negative breast cancer. <i>International Journal of Oncology</i> , 2016, 49, 265-275.	3.3	35

#	ARTICLE	IF	CITATIONS
163	Intratumoural heterogeneity of proliferation in invasive breast carcinoma evaluated with MIB1 antibody. <i>Breast</i> , 1997, 6, 171-176.	2.2	34
164	The ErbB4 CYT2 variant protects EGFR from ligand-induced degradation to enhance cancer cell motility. <i>Science Signaling</i> , 2014, 7, ra78.	3.6	34
165	Genomic analysis defines clonal relationships of ductal carcinoma in situ and recurrent invasive breast cancer. <i>Nature Genetics</i> , 2022, 54, 850-860.	21.4	34
166	The radiological appearances of invasive cribriform carcinoma of the breast. <i>Clinical Radiology</i> , 1994, 49, 693-695.	1.1	33
167	Predictors of response to second-line endocrine therapy for breast cancer. <i>Breast Cancer Research and Treatment</i> , 1997, 45, 219-224.	2.5	33
168	Pathological validation and significance of micrometastasis in sentinel nodes in primary breast cancer. <i>Breast Cancer Research</i> , 2001, 3, 113-6.	5.0	33
169	Change in Expression of ER, bcl-2 and MIB1 on Primary Tamoxifen and Relation to Response in ER Positive Breast Cancer. <i>Breast Cancer Research and Treatment</i> , 2001, 65, 135-144.	2.5	33
170	Comparison of three magnetic nanoparticle tracers for sentinel lymph node biopsy in an in vivo porcine model. <i>International Journal of Nanomedicine</i> , 2015, 10, 1235.	6.7	33
171	Mammographic size of ductal carcinoma in situ does not predict the presence of an invasive focus. <i>European Journal of Cancer</i> , 2001, 37, 459-462.	2.8	32
172	Expression of the transcription factor CTCF in invasive breast cancer: a candidate gene located at 16q22.1. <i>British Journal of Cancer</i> , 2004, 91, 1591-1596.	6.4	32
173	Non-operative breast pathology: lobular neoplasia. <i>Journal of Clinical Pathology</i> , 2006, 60, 1321-1327.	2.0	32
174	Digital imaging in the immunohistochemical evaluation of the proliferation markers Ki67, MCM2 and Geminin, in early breast cancer, and their putative prognostic value. <i>BMC Cancer</i> , 2015, 15, 546.	2.6	32
175	Macrophages orchestrate the expansion of a proangiogenic perivascular niche during cancer progression. <i>Science Advances</i> , 2021, 7, eabg9518.	10.3	32
176	Pathological-radiological correlations in benign lesions excised during a breast screening programme. <i>Clinical Radiology</i> , 1994, 49, 853-856.	1.1	31
177	Do poor-prognosis breast tumours express membrane cofactor proteins (CD46)?. <i>Cancer Immunology, Immunotherapy</i> , 2005, 54, 149-156.	4.2	30
178	Lobular in situ neoplasia and columnar cell lesions: diagnosis in breast core biopsies and implications for management. <i>Pathology</i> , 2007, 39, 208-216.	0.6	30
179	High intensity focused ultrasound in the treatment of breast fibroadenomata: results of the HIFU-F trial. <i>International Journal of Hyperthermia</i> , 2016, 32, 881-888.	2.5	30
180	Mucins in prostatic carcinoma. <i>Histopathology</i> , 1990, 16, 43-46.	2.9	29

#	ARTICLE	IF	CITATIONS
181	Prognostic factors in primary breast carcinoma.. Journal of Clinical Pathology, 1995, 48, 981-983.	2.0	29
182	“Inflammatory” breast cancer. Surgical Oncology, 2005, 14, 133-143.	1.6	29
183	Sections of the nipple and quadrants in mastectomy specimens for carcinoma are of limited value. Journal of Clinical Pathology, 2005, 58, 543-545.	2.0	29
184	Models of Breast Morphogenesis Based on Localization of Stem Cells in the Developing Mammary Lobule. Stem Cell Reports, 2015, 4, 699-711.	4.8	29
185	Pathological features of 11,337 patients with primary ductal carcinoma in situ (DCIS) and subsequent events: results from the UK Sloane Project. British Journal of Cancer, 2021, 124, 1009-1017.	6.4	29
186	HER-2 in breast cancer” methods of detection, clinical significance and future prospects for treatment. Critical Reviews in Oncology/Hematology, 2002, 43, 231-244.	4.4	28
187	HER2-HER3 dimer quantification by FLIM-FRET predicts breast cancer metastatic relapse independently of HER2 IHC status. Oncotarget, 2016, 7, 51012-51026.	1.8	28
188	Correlations between the mammographic features of screen detected invasive breast cancer and pathological prognostic factors. Breast, 1997, 6, 146-149.	2.2	27
189	Current issues in diagnostic breast pathology. Journal of Clinical Pathology, 2012, 65, 771-785.	2.0	27
190	The radiological features, diagnosis and management of screen-detected lobular neoplasia of the breast: Findings from the Sloane Project. Breast, 2016, 27, 109-115.	2.2	27
191	Microstructural models for diffusion MRI in breast cancer and surrounding stroma: an <i>ex vivo</i> study. NMR in Biomedicine, 2017, 30, e3679.	2.8	27
192	Basal phenotype: a powerful prognostic factor in small screen-detected invasive breast cancer with long-term follow-up. Journal of Medical Screening, 2007, 14, 210-214.	2.3	26
193	Lesion size is a major determinant of the mammographic features of ductal carcinoma in situ: findings from the Sloane project. Clinical Radiology, 2010, 65, 181-184.	1.1	26
194	Patterns of metastatic spread in early breast cancer. Breast, 2013, 22, 449-454.	2.2	26
195	Macroscopic handling and reporting of breast cancer specimens pre- and post- adjuvant chemotherapy treatment: review of pathological issues and suggested approaches. Histopathology, 2015, 67, 279-293.	2.9	26
196	Histological scoring of immune and stromal features in breast and axillary lymph nodes is prognostic for distant metastasis in lymph node- positive breast cancers. Journal of Pathology: Clinical Research, 2018, 4, 39-54.	3.0	26
197	An observational study showed that explaining randomization using gambling-related metaphors and computer-agency descriptions impeded randomized clinical trial recruitment. Journal of Clinical Epidemiology, 2018, 99, 75-83.	5.0	25
198	Invasion in breast lesions: the role of the epithelial “stroma barrier. Histopathology, 2018, 72, 1075-1083.	2.9	25

#	ARTICLE	IF	CITATIONS
199	A critical appraisal of existing classification systems of epithelial hyperplasia and in situ neoplasia of the breast with proposals for future methods of categorization: where are we going?. Seminars in Diagnostic Pathology, 1999, 16, 202-8.	1.5	25
200	Endocrine response and resistance in breast cancer: a role for the transcription factor Fos. , 1999, 84, 54-61.		24
201	Performance of automated scoring of ER, PR, HER2, CK5/6 and EGFR in breast cancer tissue microarrays in the Breast Cancer Association Consortium. Journal of Pathology: Clinical Research, 2015, 1, 18-32.	3.0	24
202	Family history of breast cancer and its association with disease severity and mortality. Cancer Medicine, 2016, 5, 942-949.	2.8	24
203	Phenotypic similarities in bilateral breast cancer. Breast Cancer Research and Treatment, 2004, 85, 255-261.	2.5	23
204	Frequency of Pathogenic Germline Variants in <i>CDH1</i> , <i>BRCA2</i> , <i>CHEK2</i> , <i>PALB2</i> , <i>BRCA1</i> , and <i>TP53</i> in Sporadic Lobular Breast Cancer. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 1162-1168.	2.5	23
205	DIAGNOSIS OF BREAST CANCER WITH CORE BIOPSY AND FINE NEEDLE ASPIRATION CYTOLOGY. ANZ Journal of Surgery, 1996, 66, 592-594.	0.7	22
206	High-resolution analysis of 16q22.1 in breast carcinoma using DNA amplifiable probes (multiplex) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 4 Cancer, 2005, 114, 720-729.	5.1	22
207	Diagnostic concordance of breast pathologists: lessons from the National Health Service Breast Screening Programme Pathology External Quality Assurance Scheme. Histopathology, 2017, 70, 632-642.	2.9	22
208	Identification of carcinoma cells in peripheral blood samples of patients with advanced breast carcinoma using RT-PCR amplification of CK7 and MUC1. Breast, 2004, 13, 35-41.	2.2	21
209	Successful management of elderly breast cancer patients treated without radiotherapy. World Journal of Surgical Oncology, 2007, 5, 62.	1.9	21
210	An intra-operative THz probe for use during the surgical removal of breast tumors. , 2008, , .		21
211	Pleomorphic LCIS what do we know? A UK multicenter audit of pleomorphic lobular carcinoma in situ. Breast, 2018, 38, 120-124.	2.2	21
212	Breast Cancer with Neoductgenesis: Histopathological Criteria and Its Correlation with Mammographic and Tumour Features. International Journal of Breast Cancer, 2014, 2014, 1-10.	1.2	20
213	The B3 conundrum—the radiologists' perspective. British Journal of Radiology, 2017, 90, 20160595.	2.2	20
214	Micro- and macro-metastasis in the axillary lymph node: A review. Journal of the Royal College of Surgeons of Edinburgh, 2017, 15, 76-82.	1.8	20
215	The assessment of multiple variables on breast carcinoma fine needle aspiration (FNA) cytology specimens: method, preliminary results and prognostic associations. Cytopathology, 1995, 6, 316-324.	0.7	19
216	Digital Imaging Improves Upright Stereotactic Core Biopsy of Mammographic Microcalcifications. Clinical Radiology, 2000, 55, 374-377.	1.1	19

#	ARTICLE	IF	CITATIONS
217	Implications of Inconsistent Measurement of ER Status in Non-Invasive Breast Cancer: A Study of 1,684 Cases from the Sloane Project. <i>Breast Journal</i> , 2008, 14, 33-38.	1.0	19
218	Magnetic Technique for Sentinel Lymph Node Biopsy in Melanoma: The MELAMAG Trial. <i>Annals of Surgical Oncology</i> , 2016, 23, 2070-2078.	1.5	19
219	The NHS breast screening programme (pathology) EQA: experience in recent years relating to issues involved in individual performance appraisal. <i>Journal of Clinical Pathology</i> , 2006, 59, 130-137.	2.0	18
220	Pre-operative diagnosis of breast cancer in screening: problems and pitfalls. <i>Pathology</i> , 2009, 41, 3-17.	0.6	18
221	Magnetic sentinel lymph node biopsy and localization properties of a magnetic tracer in an in vivo porcine model. <i>Breast Cancer Research and Treatment</i> , 2013, 141, 33-42.	2.5	18
222	Progression of breast cancer following locoregional ipsilateral recurrence: importance of interval time. <i>British Journal of Cancer</i> , 2016, 114, 88-95.	6.4	18
223	High-intensity focused ultrasound in the treatment of breast fibroadenomata (HIFU-F trial). <i>International Journal of Hyperthermia</i> , 2018, 34, 1002-1009.	2.5	18
224	Are Medullary Breast Cancers an Indication for BRCA1 Mutation Screening? A Mutation Analysis of 42 Cases of Medullary Breast Cancer. <i>Breast Cancer Research and Treatment</i> , 2004, 85, 81-88.	2.5	17
225	Adverse surgical outcomes in screen-detected ductal carcinoma in situ of the breast. <i>European Journal of Cancer</i> , 2014, 50, 1880-1890.	2.8	17
226	Nottingham Clinico-Pathological Response Index (NPRI) after Neoadjuvant Chemotherapy (Neo-ACT) Accurately Predicts Clinical Outcome in Locally Advanced Breast Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 1052-1062.	7.0	17
227	Selection and evolution in the genomic landscape of copy number alterations in ductal carcinoma in situ (DCIS) and its progression to invasive carcinoma of ductal/no special type: a meta-analysis. <i>Breast Cancer Research and Treatment</i> , 2015, 153, 101-121.	2.5	17
228	Diagnostic concordance of reporting lymphovascular invasion in breast cancer. <i>Journal of Clinical Pathology</i> , 2018, 71, 802-805.	2.0	17
229	Frequency of pathogenic germline variants in BRCA1, BRCA2, PALB2, CHEK2 and TP53 in ductal carcinoma in situ diagnosed in women under the age of 50 years. <i>Breast Cancer Research</i> , 2019, 21, 58.	5.0	17
230	Prognostic and Predictive Value of HER2 Expression in Ductal Carcinoma <i>In Situ</i> : Results from the UK/ANZ DCIS Randomized Trial. <i>Clinical Cancer Research</i> , 2021, 27, 5317-5324.	7.0	17
231	A review of ablative techniques in the treatment of breast fibroadenomata. <i>Journal of Therapeutic Ultrasound</i> , 2016, 4, 1.	2.2	16
232	An audit of residual cancer burden reproducibility in a UK context. <i>Histopathology</i> , 2017, 70, 217-222.	2.9	16
233	Molecular patterns of cancer colonisation in lymph nodes of breast cancer patients. <i>Breast Cancer Research</i> , 2018, 20, 143.	5.0	16
234	Variability in grading of ductal carcinoma <i>in situ</i> among an international group of pathologists. <i>Journal of Pathology: Clinical Research</i> , 2021, 7, 233-242.	3.0	16

#	ARTICLE	IF	CITATIONS
235	<title>Diffraction-enhanced imaging: improved contrast and lower dose x-ray imaging</title>. , 2002, , .		15
236	HER2 status in breast cancer—an example of pharmacogenetic testing. <i>Journal of the Royal Society of Medicine</i> , 2007, 100, 326-329.	2.0	15
237	Comparison of margin assessment by radial and shave sections in wide local excision specimens for invasive carcinoma of the breast. <i>Histopathology</i> , 2010, 56, 573-580.	2.9	15
238	HER2 testing for breast carcinoma: recommendations for rapid diagnostic pathways in clinical practice. <i>Journal of Clinical Pathology</i> , 2014, 67, 161-167.	2.0	15
239	Reporting needle core biopsies of breast carcinomas. <i>Histopathology</i> , 2003, 43, 84-90.	2.9	14
240	Pathological Controversies in Breast Cancer: Classification of Ductal Carcinoma In Situ, Sentinel Lymph Nodes and Low Volume Metastatic Disease and Reporting of Neoadjuvant Chemotherapy Specimens. <i>Clinical Oncology</i> , 2013, 25, 80-92.	1.4	14
241	PIK3CA mutations are common in lobular carcinoma in situ, but are not a biomarker of progression. <i>Breast Cancer Research</i> , 2017, 19, 7.	5.0	14
242	Invasive breast cancer over four decades reveals persisting poor metastatic outcomes in treatment resistant subgroup — the —ATRESS—phenomenon. <i>Breast</i> , 2020, 50, 39-48.	2.2	14
243	Assessment of structural chromosomal instability phenotypes as biomarkers of carboplatin response in triple negative breast cancer: the TNT trial. <i>Annals of Oncology</i> , 2021, 32, 58-65.	1.2	14
244	Detecting which invasive cancers at mammographic screening saves lives?. <i>Journal of Medical Screening</i> , 2001, 8, 86-90.	2.3	13
245	Accuracy of mammography in predicting histological extent of ductal carcinoma in situ (DCIS). <i>European Journal of Surgical Oncology</i> , 2006, 32, 1089-1092.	1.0	13
246	Comparative Immunohistochemical Analysis of Ochratoxin A Tumourigenesis in Rats and Urinary Tract Carcinoma in Humans; Mechanistic Significance of p-S6 Ribosomal Protein Expression. <i>Toxins</i> , 2012, 4, 643-662.	3.4	13
247	Breast conservation in ductal carcinoma <i>in situ</i> (DCIS): what defines optimal margins?. <i>Histopathology</i> , 2017, 70, 681-692.	2.9	13
248	Metaplastic carcinomas of the breast without evidence of epithelial differentiation: a diagnostic approach for management. <i>Histopathology</i> , 2021, 78, 759-771.	2.9	13
249	Prognostic factors in invasive carcinoma of the breast. <i>Clinical Oncology</i> , 1998, 10, 14-17.	1.4	12
250	Extent of ductal carcinoma in situ within and surrounding invasive primary breast carcinoma. <i>British Journal of Surgery</i> , 2002, 88, 1324-1329.	0.3	12
251	HER2 status in breast cancer—an example of pharmacogenetic testing. <i>Journal of the Royal Society of Medicine</i> , 2007, 100, 326-329.	2.0	12
252	Splicing imbalances in basal-like breast cancer underpin perturbation of cell surface and oncogenic pathways and are associated with patients' survival. <i>Scientific Reports</i> , 2017, 7, 40177.	3.3	12

#	ARTICLE	IF	CITATIONS
253	Unresected screen-detected ductal carcinoma in situ: Outcomes of 311 women in the Forget-Me-Not 2 study. <i>Breast</i> , 2022, 61, 145-155.	2.2	12
254	Pathological assessment of sentinel lymph-node biopsies in patients with breast cancer. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2000, 436, 97-101.	2.8	11
255	Retrospective observational study of HER2 immunohistochemistry in borderline breast cancer patients undergoing neoadjuvant therapy, with an emphasis on Group 2 (HER2/CEP17 ratio ≤ 2.0 , HER2) Tj ETQq 1 0.784314 rg 51	1.0	14
256	Microinvasive carcinoma of the breast: diagnostic criteria and clinical relevance. <i>Histopathology</i> , 1999, 35, 470-472.	2.9	10
257	Grade of recurrent in situ and invasive carcinoma following treatment of pure ductal carcinoma in situ of the breast. <i>British Journal of Cancer</i> , 2004, 90, 1538-1542.	6.4	10
258	Modern therapies and iatrogenic changes in breast pathology. <i>Histopathology</i> , 2017, 70, 40-55.	2.9	10
259	Mammographic and pathological features of breast cancer detected at first incident round screening. <i>Breast</i> , 1997, 6, 259-265.	2.2	9
260	Is Mammography of Value in Women with Disseminated Cancer of Unknown Origin?. <i>Clinical Oncology</i> , 1999, 11, 90-92.	1.4	9
261	Synchronous ductal carcinoma in situ of the breast and within epithelial inclusions in an ipsilateral sentinel lymph node. <i>Human Pathology</i> , 2013, 44, 142-144.	2.0	9
262	Discrepancies in central review re-testing of patients with ER-positive and HER2-negative breast cancer in the OPTIMA prelim randomised clinical trial. <i>British Journal of Cancer</i> , 2017, 116, 859-863.	6.4	9
263	Confusion Over Differences in Registration and Randomization Criteria for the LORIS (Low-Risk DCIS) Trial. <i>Annals of Surgical Oncology</i> , 2017, 24, 566-567.	1.5	9
264	Prognostic Value of ER and PgR Expression and the Impact of Multi-clonal Expression for Recurrence in Ductal Carcinoma <i>in situ</i> : Results from the UK/ANZ DCIS Trial. <i>Clinical Cancer Research</i> , 2021, 27, 2861-2867.	7.0	9
265	Systemic immune reaction in axillary lymph nodes adds to tumor-infiltrating lymphocytes in triple-negative breast cancer prognostication. <i>Npj Breast Cancer</i> , 2021, 7, 86.	5.2	9
266	Low-risk DCIS. What is it? Observe or excise?. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2022, 480, 21-32.	2.8	9
267	Precursor lesions of breast carcinoma. <i>Breast</i> , 1993, 2, 220-223.	2.2	8
268	Oncological Outcomes in Rats Given Nephrocarcinogenic Exposure to Dietary Ochratoxin A, Followed by the Tumour Promoter Sodium Barbitol for Life: A Pilot Study. <i>Toxins</i> , 2010, 2, 552-571.	3.4	8
269	Optimising magnetic sentinel lymph node biopsy in an in vivo porcine model. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2015, 11, 993-1002.	3.3	8
270	Needle core biopsy of the breast. <i>Current Diagnostic Pathology</i> , 2000, 6, 200-205.	0.4	7

#	ARTICLE	IF	CITATIONS
271	Non-operative breast pathology. <i>Journal of Clinical Pathology</i> , 2006, 60, 1297-1299.	2.0	7
272	Low-grade adenosquamous carcinoma arising in association with a nipple adenoma. <i>Histopathology</i> , 2020, 76, 784-787.	2.9	7
273	United Kingdom national audit of breast fine needle aspiration cytology in 1990-91-organization and level of activity. <i>Cytopathology</i> , 1996, 7, 316-325.	0.7	6
274	Viewpoint: Availability of oestrogen receptor and HER2 status for the breast multidisciplinary meeting discussion; time to get it right. <i>European Journal of Surgical Oncology</i> , 2016, 42, 994-998.	1.0	6
275	The importance of histological assessment after neoadjuvant therapy and the need for standardisation. <i>Clinical Radiology</i> , 2018, 73, 693-699.	1.1	6
276	Bilateral breast carcinomas: Do they have similar mammographic features?. <i>Clinical Radiology</i> , 1999, 54, 434-437.	1.1	5
277	Metastatic Carcinoma of the Breast with Tubular Features: Differences Compared with Metastatic Ductal Carcinoma of No Specific Type. <i>Clinical Oncology</i> , 2004, 16, 119-124.	1.4	5
278	An Immunohistochemical and Fluorescence In Situ Hybridization-based Comparison Between the Oracle HER2 Bond Immunohistochemical System, Dako HercepTest, and Vysis PathVysion HER2 FISH Using Both Commercially Validated and Modified ASCO/CAP and United Kingdom HER2 IHC Scoring Guidelines. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2010, 18, 489-493.	1.2	5
279	Assessment of microtubule-associated protein (MAP)-Tau expression as a predictive and prognostic marker in TACT; a trial assessing substitution of sequential docetaxel for FEC as adjuvant chemotherapy for early breast cancer. <i>Breast Cancer Research and Treatment</i> , 2014, 144, 331-341.	2.5	5
280	Gene expression modules in primary breast cancers as risk factors for organotropic patterns of first metastatic spread: a case control study. <i>Breast Cancer Research</i> , 2017, 19, 113.	5.0	5
281	Real-time <i>ex vivo</i> perfusion of human lymph nodes invaded by cancer (REPLICANT): a feasibility study. <i>Journal of Pathology</i> , 2020, 250, 262-274.	4.5	5
282	Proteomics of REPLICANT perfusate detects changes in the metastatic lymph node microenvironment. <i>Npj Breast Cancer</i> , 2021, 7, 24.	5.2	5
283	Invasive Carcinoma: Special Types. , 2006, , 201-223.		5
284	A multi-modal exploration of heterogeneous physicochemical properties of DCIS breast microcalcifications. <i>Analyst</i> , 2022, 147, 1641-1654.	3.5	5
285	Breast cancer diagnosis using scattered x rays?. , 2001, 4320, 547.		4
286	Terahertz pulsed imaging and spectroscopy of breast tumors. , 2006, 6386, 178.		4
287	Application of Finite Difference Time Domain methods to Terahertz Spectroscopy Measurements of Breast Cancer. <i>IEEE MTT-S International Microwave Symposium Digest IEEE MTT-S International Microwave Symposium</i> , 2007, , .	0.0	4
288	Pathological Nipple Discharge. <i>Open Access Journal of Science and Technology</i> , 2014, 2, .	0.2	4

#	ARTICLE	IF	CITATIONS
289	OPTIMA (Optimal Personalised Treatment of early breast cancer using Multi-parameter Analysis): A prospective trial to validate the predictive utility and cost-effectiveness of gene expression test-directed chemotherapy decisions.. Journal of Clinical Oncology, 2016, 34, TPS623-TPS623.	1.6	4
290	UK national audit of breast fine needle aspiration cytology in 1990-91: diagnostic criteria. Cytopathology, 1996, 7, 326-332.	0.7	3
291	Ductal carcinoma in situ: diagnosis and classification. Current Diagnostic Pathology, 2004, 10, 204-210.	0.4	3
292	Reproducibility of cancer diagnosis using hair. International Journal of Cancer, 2006, 118, 1060-1060.	5.1	3
293	Immunohistochemistry for Triple-Negative Breast Cancer. Methods in Molecular Biology, 2016, 1406, 39-51.	0.9	3
294	In situ lobular proliferations of the breast. Diagnostic Histopathology, 2018, 24, 58-63.	0.4	3
295	Fibroepithelial Lesions, Including Fibroadenoma and Phyllodes Tumors. , 2011, , 121-138.		3
296	Invasive Lobular Carcinoma of the Breast. Surgical Pathology Clinics, 2012, 5, 545-566.	1.7	2
297	Ductal carcinoma in situ: current morphological and molecular subtypes. Diagnostic Histopathology, 2012, 18, 112-118.	0.4	2
298	Minimum slice spacing required to reconstruct 3D shape for serial sections of breast tissue for comparison with medical imaging. , 2015, , .		2
299	Accuracy of classification of invasive lobular carcinoma on needle core biopsy of the breast: Table 1. Journal of Clinical Pathology, 2016, 69, 1122-1123.	2.0	2
300	The impact of human epidermal growth factor receptor 2 neoadjuvant monoclonal antibody (trastuzumab) therapy in ductal carcinoma <i>in situ</i> of the breast. Histopathology, 2017, 70, 1009-1011.	2.9	2
301	Reply to "Comment on: Pathological features of 11,337 patients with primary ductal carcinoma in situ (DCIS) and subsequent events: results from the UK Sloane Project". British Journal of Cancer, 2021, 124, 1463-1464.	6.4	2
302	Performance of automated scoring of ER, PR, HER2, CK5/6 and EGFR in breast cancer tissue microarrays in the Breast Cancer Association Consortium. The Clinical Journal of Pathology, 2014, , n/a-n/a.	0.0	2
303	Invasive Carcinoma. , 2011, , 272-278.		2
304	Abstract P4-07-04: Genomic analysis of paired DCIS and subsequent recurrence to assess clonal relatedness in screen detected DCIS. , 2020, , .		2
305	Fibroepithelial Lesions, Including Fibroadenoma and Phyllodes Tumor. , 2006, , 109-124.		2
306	Bilateral Inflammatory Pseudotumour of the Breast: A Case Report and Review of the Literature. The Journal of Breast Health, 2018, 14, 229-233.	1.0	2

#	ARTICLE	IF	CITATIONS
307	Proliferative activity in invasive breast carcinoma.. Journal of Clinical Pathology, 1996, 49, 868-869.	2.0	1
308	Invited Editorial. Cytopathology, 1998, 9, 289-290.	0.7	1
309	Comments onSynchrotron fibre diffraction identifies and locates foetal collagenous breast tissue associated with breast carcinomaby V. J. James (2002).J. Synchrotron Rad.9, 71â€“76. Journal of Synchrotron Radiation, 2003, 10, 199-199.	2.4	1
310	Editorial. Histopathology, 2008, 52, 1-2.	2.9	1
311	Experts and performance in histopathologyâ€”A study in breast pathology. Pathology Research and Practice, 2010, 206, 749-752.	2.3	1
312	Addendum to BASOII Trial report. European Journal of Cancer, 2014, 50, 2517-2518.	2.8	1
313	Classification of breast cancer stroma as a tool for prognosis. Proceedings of SPIE, 2016, , .	0.8	1
314	Reply to R.F. Sweis et al. Journal of Clinical Oncology, 2017, 35, 261-262.	1.6	1
315	Concordance of intrinsic subtyping and risk of recurrence (ROR) scores between matched primary and metastatic tissue from Triple Negative Breast Cancer Trial (TNT).. Journal of Clinical Oncology, 2015, 33, 1019-1019.	1.6	1
316	Treatment and outcomes from a large, prospective, national longitudinal cohort study of screen detected ductal carcinoma in situ (DCIS).. Journal of Clinical Oncology, 2016, 34, 1570-1570.	1.6	1
317	Impact of COVID-19 on the practice of breast pathologists: a survey of breast pathologists in the UK and Ireland. Journal of Clinical Pathology, 2023, 76, 234-238.	2.0	1
318	Invasive Carcinoma: Other Histologic Prognostic Factors â€” Size, Vascular Invasion and Prognostic Index. , 2006, , 235-240.		1
319	Core Biopsy. , 2011, , 19-27.		1
320	Invasive Carcinoma. , 2011, , 227-259.		1
321	Breast calcification micromorphology classification. British Journal of Radiology, 2022, 95, .	2.2	1
322	Selective use of post-mastectomy flap irradiation in high-risk breast cancer patients. Breast, 2005, 14, 298-303.	2.2	0
323	Pathology of the breast. Diagnostic Histopathology, 2008, 14, 459-464.	0.4	0
324	Pathology: ductal carcinoma in situ and lesions of uncertain malignant potential. , 0, , 127-145.		0

#	ARTICLE	IF	CITATIONS
325	Ductal Carcinoma in Situ. , 2018, , 115-126.		0
326	Pathology of High-Risk Breast Lesions. , 2018, , 103-114.		0
327	Screening detects a myriad of breast disease â€œ refining practice will increase effectiveness and reduce harm. British Journal of Radiology, 2020, 93, 20200135.	2.2	0
328	Histological risk factors, prognostic indicators. , 2005, , 254-265.		0
329	Assessment of Fine Needle Aspiration Cytology and Core Biopsy Samples. , 2006, , 17-27.		0
330	Benign Stromal Lesions of the Breast. , 2006, , 125-137.		0
331	Morphology of Ductal Carcinoma in situ. , 2006, , 191-200.		0
332	Diagnostic Methodologies: Core Biopsy and Handling of Surgical Specimens. , 2006, , 11-16.		0
333	Overview of Immunohistochemistry in Breast Lesions. , 2006, , 275-282.		0
334	Breast: Ductal Carcinoma In Situ (DCIS). , 2011, , 421-436.		0
335	Histological risk factors, prognostic indicators and staging. , 2013, , 236-249.		0
336	Modelling Vascularity in Breast Cancer and Surrounding Stroma Using Diffusion MRI and Intravoxel Incoherent Motion. Lecture Notes in Computer Science, 2014, , 380-386.	1.3	0
337	Proliferative Breast Lesions. , 2017, , 33-41.		0
338	Problematic Core Biopsies. , 2017, , 43-60.		0